RWQ Financial Management Services Inc. Buys 31,510 Shares of AbbVie Inc. $ABBV

RWQ Financial Management Services Inc. grew its position in AbbVie Inc. (NYSE:ABBV) by 135.9% during the second quarter, HoldingsChannel reports. The firm owned 54,700 shares of the company’s stock after buying an additional 31,510 shares during the quarter. AbbVie comprises approximately 6.6% of RWQ Financial Management Services Inc.’s holdings, making the stock its 5th biggest position. RWQ Financial Management Services Inc.’s holdings in AbbVie were worth $13,765,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of AbbVie by 5.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 495,003 shares of the company’s stock worth $124,563,000 after buying an additional 27,237 shares during the period. Hidden Cove Wealth Management LLC raised its holdings in AbbVie by 16.5% in the 2nd quarter. Hidden Cove Wealth Management LLC now owns 2,600 shares of the company’s stock worth $654,000 after acquiring an additional 369 shares during the period. E Fund Management Hong Kong Co. Ltd. raised its holdings in AbbVie by 368.4% in the 2nd quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,288 shares of the company’s stock worth $324,000 after acquiring an additional 1,013 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in AbbVie by 1.1% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 324,551 shares of the company’s stock worth $81,670,000 after acquiring an additional 3,394 shares during the last quarter. Finally, MFA Wealth Services lifted its position in AbbVie by 11.8% during the 2nd quarter. MFA Wealth Services now owns 3,401 shares of the company’s stock worth $856,000 after acquiring an additional 358 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABBV. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Canaccord Genuity Group boosted their price objective on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Barclays increased their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Cantor Fitzgerald raised their target price on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Finally, Citigroup lifted their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $275.50.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Stock Performance

NYSE:ABBV opened at $249.20 on Friday. The firm’s 50-day moving average is $244.94 and its 200-day moving average is $226.12. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market cap of $440.29 billion, a price-to-earnings ratio of 70.40, a PEG ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the business earned $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.